Author

Neus Domper

Observed names: N. Domper Rubio, Neus Domper Rubio, Neus Domper-Rubio

Institution: Adc Therapeutics (Switzerland)

Observed institutions: Adc Therapeutics (Switzerland), Celgene (Switzerland)

OpenAlex ID: A5028977159

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

2021 · Grzegorz S. Nowakowski, Wolfgang Willenbacher, et al. · International Journal of Hematology · 18

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

2019 · Grzegorz S. Nowakowski, Wolfgang Willenbacher, et al. · Journal of Clinical Oncology · 10

Safety and Efficacy of the Pd‐l1 Inhibitor Durvalumab With R‐chop or R2‐chop in Subjects With Previously Untreated, High‐risk Dlbcl

2019 · G. Nowakowski, W. Willenbacher, et al. · Hematological Oncology · 7

ABCL-758: Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL

2025 · Carmelo Carlo-Stella, Michal T. Kwiatek, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Zuma-25: A Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) Chimeric Antigen Receptor T-Cell Therapy in Adult Patients with Relapsed/Refractory Rare B-Cell Malignancies

2023 · Barbara Eichhorst, Kieron Dunleavy, et al. · Transplantation and Cellular Therapy · 1

POSTER: ABCL-758 Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL

2025 · Carmelo Carlo-Stella, Michal T. Kwiatek, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 6

Citation count: 37

H-index: 3

I10-index: 2